<DOC>
	<DOCNO>NCT01311661</DOCNO>
	<brief_summary>This study compare efficacy safety different regimen olodaterol administration asthma ( daily , twice daily ) placebo complete cross-over design within one two daily dose group ( medium high daily dose ) .</brief_summary>
	<brief_title>A Study Compare Efficacy Safety Different Dosings Olodaterol Administered With Respimat® Inhaler Patients With Moderate Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients either sex . 2 . Aged 18 70 year . 3 . A current diagnosis document minimum 3 month history asthma Global Initiative Asthma ( GINA ) treatment step 3 4 . 4 . Prebronchodilator Forced Expiratory Volume one second ( FEV1 ) &gt; = 60 % predict &lt; 90 % predict accord European Coal Steel Community ( ECSC ) . 5 . Increase FEV1 &gt; =12 % &gt; =200 mL 15 min . 400 µg salbutamol ( albuterol ) ; 6 . Stable medium high dose inhale corticosteroid ( ICS ) low high dose ICS combination long act betaadrenergics ( LABA ) least 6 week prior screen . Stable ICS mono component former fix LABA/ICS treatment least 48 hour prior Visit 1b . Exclusion criterion : 1 . Patients significant disease asthma . 2 . History frequent seasonal exacerbation asthma ( defined one seasonal exacerbation every year past three year ) . 3 . Upper respiratory tract infection past 3 week prior screen visit 1b . 4 . Oral systemic corticosteroid past 6 week . 5 . Patients allergen desensitization therapy start within two year , establish maintenance regimen characterize dose adjustment increase tolerable maximum course immunotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>